← Issue №12/ week of Sep 20, 2026/Hepatology

Risk Factors and Definition of Younger-Onset Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Cirrhosis.

From GI Signals issue №12: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology retrospective · n=2,395 · Sep 16, 2026 · Clin Gastro Hep · IF 16.2

Risk Factors and Definition of Younger-Onset Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Cirrhosis.

New evidencecirrhosisMASLDepidemiology
Clinical takeawayIn MASLD patients under 50 with T2DM or BMI ≥35kg/m2, consider heightened surveillance for cirrhosis given their higher genetic risk (PNPLA3, TM6SF2, HSD17B13 alleles) and metabolic burden, per standard diabetes and MASLD management.
What it found25% of MASLD cirrhosis cases present before age 50, associated with high genetic risk score (OR 2.33, dichotomized at median) and T2DM (OR 3.74).
ContextRefines understanding of MASLD cirrhosis risk beyond age, highlighting a high-risk younger subgroup (<50 years) with distinct genetic and metabolic drivers.
Refinessuggested applicable standard· American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149

Decision at stakescreening all T2DM for MASLD with FIB-4

Manage diabetes in GI/hepatology patients by individualizing the A1c target to the population, in cirrhosis, A1c is unreliable because altered red blood cell turnover typically underestimates glycemia, so set glycemic goals using blood glucose monitoring and/or CGM rather than a fixed A1c cutoff, and in diabetic gastroparesis individualize the target rather than applying a universal cutoff; ≤7% pre-bariatric, <6.5% pre-conception, while screening all T2DM for MASLD with FIB-4, screening T1DM for concurrent celiac disease, and screening for diabetic gastroparesis when chronic nausea, early satiety, or postprandial fullness are present.

From our summary of this standard, unedited — the part the paper bears on. marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Manage diabetes in GI/hepatology patients by individualizing the A1c target to the population, in cirrhosis, A1c is unreliable because altered red blood cell turnover typically underestimates glycemia, so set glycemic goals using blood glucose monitoring and/or CGM rather than a fixed A1c cutoff, and in diabetic gastroparesis individualize the target rather than applying a universal cutoff; ≤7% pre-bariatric, <6.5% pre-conception, while screening all T2DM for MASLD with FIB-4, screening T1DM for concurrent celiac disease, and screening for diabetic gastroparesis when chronic nausea, early satiety, or postprandial fullness are present. Evaluate new-onset DM after age 50 without obesity for a pancreatic cancer differential, and coordinate peri-procedural medication holds and multidisciplinary endocrinology involvement.

American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149 · reviewed 2026-07-23 ↗
Ajmera V … Loomba R · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
← Read the whole of issue №12 Every paper GI Signals surfaces gets a page like this one. All issues